(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) released a statement today following President Trump’s Executive Order on drug pricing.

“America’s pharmacy benefit managers (PBMs) continue to share the administration’s goal of lowering prescription drug costs for the American people and reducing health care premiums for America’s seniors.

“PBMs responded to President Trump’s call to make insulin more affordable by offering innovative solutions in the market, leveraging competition as it became available, and adding to the public pressure on Big Pharma to lower the prices they set on the drugs they market. We are ready to work with the White House, plan sponsors, and other stakeholders on solutions that will effectively lower prices and improve outcomes for patients — while protecting the Part D program and beneficiaries from premium hikes and lost access to pharmacy options.

“We will also continue to innovate new market-based approaches to deliver lower out-of-pocket costs, inject more transparency into the system, and support our partners in the pharmacy community.”

###

PCMA is the national association representing America’s pharmacy benefit companies. Pharmacy benefit companies are working every day to secure savings, enable better health outcomes, and support access to quality prescription drug coverage for more than 275 million patients.